Tech Company Financing Transactions

Caribou Biosciences Funding Round

Farallon Capital Management, Partner Fund Management and Ridgeback Capital participated in a $115 million Series C funding round for Caribou Biosciences. This venture round was announced on 3/4/2021.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

2929 7th St. 105
Berkeley, CA 94710
USA

Phone

(510) 982-6030

Website

www.cariboubio.com

Email Address

[email protected]

Overview

Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Rachel Haurwitz

        

Chief Financial Officer

Jason O'Byrne

        

Chief Scientific Officer

Steven Kanner

        

Vice President

Chris Fuller

        

Vice President

Justin Skoble

        

Vice President

Cherry Thomas

        

VP - Finance

Ryan Fischesser

        

VP - General Counsel

Barbara McClung

        

VP - Human Resources

Cindy Hayashi

        

VP - R & D

Scott Gradia

        

VP - Regulatory Affairs

Elaine Alambra

        

Browse more venture capital transactions:

Prev: 3/4/2021: Clari venture capital transaction
Next: 3/4/2021: Turntide Technologies venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary